VivoSeq
Other

Carbon Dioxide

0

Pipeline Programs

1

Active Trials

2

Companies Involved

Carbon Dioxide is an early-stage landscape with 0 programs across 2 companies. The most active players are GSK, Cerevel Therapeutics, LLC.

Pipeline Metrics

Competitive Density

6/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

88/100

Attrition Rate

8/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Programs by Phase

No pipeline programs currently tracked for this disease.

Trial Status

13

clinical trials

Completed7 · 54%
Unknown status4 · 31%
Recruiting1 · 8%
Terminated1 · 8%

Trial Activity

13 trials

The Value of Central Venous-arterial Carbon Dioxide Difference
Completed··N/A·NCT04761237·118 enrolled
CO2 (Carbon Dioxide) - Cerebral Oxygenation
Completed·UUniversity of Zurich·Phase 2·NCT03338907·30 enrolled
Market Potential of Carbon Dioxide Nasal Spray
Completed·GSK logoGSK·Phase 2·NCT02113449·147 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)